Last data update: May 28, 2024. (Total: 46864 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: McLaurin T [original query] |
---|
HIV-1 evolution in breakthrough infections in a human trial of oral pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil fumarate
Ruone S , Paxton L , McLaurin T , Taylor A , Hanson D , Heneine W , Brooks JT , Garcia-Lerma JG . J Acquir Immune Defic Syndr 2015 72 (2) 129-32 We describe HIV-1 evolutionary dynamics in the four participants from the TDF2-PrEP trial who became HIV-1-infected while prescribed FTC/TDF. At seroconversion, virus diversity in the 2 participants with detectable drug was only 0.05% (95% CI=0.04-0.06) and 0.07% (0.06-0.08) compared to 2.25% (1.95-2.6) and 0.42% (0.36-0.49) in those with no detectable drug, and 0.07%-0.69% in placebo recipients (p>0.5). At 10 months, diversity in adherent participants was only 0.37% (0.31-0.41) and 0.86% (0.82-0.90) compared to 0.5%-1.7% among participants that did not take FTC/TDF (p>0.5). Although limited by the small number of infections that reduced the power to detect differences, we found that sequences from seroconverters with detectable drug were more homogeneous than those from placebo or non-adherent seroconverters. |
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial
Caixeta A , Stone GW , Mehran R , Lee EA , McLaurin BT , Cox DA , Bertrand ME , Lincoff AM , Moses JW , White HD , Ohman EM , Palmerini T , Syros G , Kittas C , Fahy M , Hooper WC , Lansky AJ , Dangas GD . J Thromb Thrombolysis 2011 31 (2) 154-64 We sought to evaluate the association between C-reactive protein (CRP) sampled on admission and short- and long-term mortality in patients with acute coronary syndromes (ACS) undergoing early invasive treatment. Baseline levels of CRP were determined in 2,974 patients with moderate and high-risk ACS undergoing an early invasive treatment strategy in the large-scale randomized ACUITY trial. The relationship of CRP to 30-day and 1-year clinical outcomes were assessed according to quartiles of CRP values. Patients with CRP levels in the fourth quartile compared to the first quartile had significantly higher 30-day mortality (2.3 vs. 0.3%, P = 0.0004) and 1-year mortality (5.5 vs. 2.8%, P = 0.0003). CRP level as a continuous variable was associated with 30-day mortality (OR [95% CI] for one unit increase in logarithmically transformed CRP level = 1.42 [1.08-1.89], P = 0.01) and 1-year mortality (OR [95% CI] = 1.24, [1.04-1.47], P = 0.02). By multivariable analysis, higher baseline CRP levels independently predicted 30-day and 1-year mortality, a relationship that was particularly strong for patients with the highest quartile of CRP (OR [95% CI] = 5.19 [1.14-23.68], P = 0.009). In troponin-positive patients, increasing quartiles of CRP were associated with a trend for 30-day mortality (P (trend) = 0.08) and a significant increase in 1-year mortality (P (trend) = 0.02); this relationship was not present in troponin-negative patients. Baseline CRP level is a powerful independent predictor of both early and late mortality in patients with ACS being treated with an early invasive strategy, especially in troponin positive patients. |
Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment
Pretty JR , Connor TH , Spasojevic I , Kurtz KS , McLaurin JL , B' Hymer C , Debord DG . J Oncol Pharm Pract 2010 18 (1) 23-36 CONTEXT: Healthcare worker exposure to antineoplastic drugs continues to be reported despite safe handling guidelines published by several groups. Sensitive sampling and analytical methods are needed so that occupational safety and health professionals may accurately assess environmental and biological exposure to these drugs in the workplace. OBJECTIVE: To develop liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) analytical methods for measuring five antineoplastic drugs in samples from the work environment, and to apply these methods in validating sampling methodology. A single method for quantifying several widely used agents would decrease the number of samples required for method development, lower cost, and time of analysis. Methods for measuring these drugs in workers' urine would also be useful in monitoring personal exposure levels. RESULTS: LC-MS/MS methods were developed for individual analysis of five antineoplastic drugs in wipe and air sample media projected for use in field sampling: cyclophosphamide, ifosfamide, paclitaxel, doxorubicin, and 5-fluorouracil. Cyclophosphamide, ifosfamide, and paclitaxel were also measured simultaneously in some stages of the work. Extraction methods for air and wipe samples were developed and tested using the aforementioned analytical methods. Good recoveries from the candidate air and wipe sample media for most of the compounds, and variable recoveries for test wipe samples depending on the surface under study, were observed. Alternate LC-MS/MS methods were also developed to detect cyclophosphamide and paclitaxel in urine samples. CONCLUSIONS: The sampling and analytical methods were suitable for determining worker exposure to antineoplastics via surface and breathing zone contamination in projected surveys of healthcare settings. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 28, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure